Bosh sahifaABBV34 • BVMF
add
AbbVie
Yopilish kursi
62,90 R$
Kunlik diapazon
62,90 R$ - 63,90 R$
Yillik diapazon
54,36 R$ - 79,10 R$
Bozor kapitalizatsiyasi
322,03 mlrd USD
Oʻrtacha hajm
5,63 ming
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | mar, 2025info | Y/Y qiyosi |
---|---|---|
Daromad | 13,34 mlrd | 8,39% |
Joriy xarajat | 5,28 mlrd | 8,44% |
Sof foyda | 1,29 mlrd | -6,06% |
Sof foyda marjasi | 9,64 | -13,31% |
Har bir ulushga tushum | 2,46 | 6,49% |
EBITDA | 6,10 mlrd | 11,89% |
Amaldagi soliq stavkasi | 22,40% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | mar, 2025info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 5,18 mlrd | -71,35% |
Jami aktivlari | 136,16 mlrd | -8,54% |
Jami passivlari | 134,70 mlrd | -4,35% |
Umumiy kapital | 1,46 mlrd | — |
Tarqatilgan aksiyalar | 1,77 mlrd | — |
Narxi/balansdagi bahosi | 78,62 | — |
Aktivlardan daromad | 7,48% | — |
Kapitaldan daromad | 14,21% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | mar, 2025info | Y/Y qiyosi |
---|---|---|
Sof foyda | 1,29 mlrd | -6,06% |
Operatsiyalardan naqd pul | 1,64 mlrd | -59,53% |
Sarmoyadan naqd pul | -735,00 mln | 92,33% |
Moliyadan naqd pul | -1,26 mlrd | -111,63% |
Naqd pulning sof oʻzgarishi | -349,00 mln | -106,64% |
Boʻsh pul | 1,12 mlrd | -73,12% |
Haqida
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Tashkil etilgan
10-apr, 2012
Sayt
Xodimlar soni
55 000